Powered by: Motilal Oswal
2025-06-02 12:44:52 pm | Source: Motilal Oswal Financial services Ltd
Healthcare Sector Update : Chronic therapies drive YoY growth; respiratory witnesses revival by Motilal Oswal Financial Services Ltd
Healthcare Sector Update : Chronic therapies drive YoY growth; respiratory witnesses revival by Motilal Oswal Financial Services Ltd

Chronic therapies drive YoY growth; respiratory witnesses revival

* The India pharma market (IPM) grew 7.4% YoY in Apr’25 (vs. 9% in Apr’24 and 9.3% in Mar’25).

* The growth was driven by strong outperformance in Cardiac/CNS/Respiratory therapies, which outperformed IPM by 360bp/210bp/130bp. Notably, respiratory therapies saw revival in YoY growth in Apr’25.

* Acute therapy growth stood at 6% in Apr’25 (vs. 6% in Apr’24 and 8% Mar’25) owing to seasonality.

* For the 12 months ending in Apr’25, IPM growth was led by price/new launches/volume growth of 4.3%/2.3%/1.3% YoY.

* Out of the top 10 brands, Electral/Udiliv clocked a growth of 25%/22% YoY to INR900m/INR650m in Apr’25.

* In Apr’25, Mixtard/Lantus posted a decline of 11% each to INR670m/INR470m.

* Out of the top 40 brands, Alburel/Rybelsus grew 128%/54% YoY in Apr’25.

 

JB Chemicals/Glenmark/Dr Reddy outperform in Apr’25

* In Apr’25, among the top-20 pharma companies, JB Chem (up 12.3% YoY), Glenmark (up 13% YoY), and DRRL (up 12.1% YoY) recorded higher growth rates vs. IPM.

* Sanofi declined YoY by 2.5% while Glaxo/Alembic were the major laggards in Apr’25 (YoY growth of just 2.4%/2.2%).

* DRRL outperformed IPM, led by strong double-digit growth across key therapies, like Respiratory/Derma/Vaccines.

* JB Chemicals outperformed IPM, led by strong show in Cardiac/ophthal/Gastro.

* Glenmark outperformed IPM, led by double-digit growth in Cardiac/AntiIneffectives/Derma/Respiratory.

* JB reported industry-leading price growth of 6.5% YoY on the MAT basis. IPCA reported the highest volume growth of 4.8% YoY on MAT basis. Dr. Reddy posted the highest growth in new launches (up 4.5% YoY).

 

Cardiac/Gastro/Antineoplast/Urology lead YoY growth on MAT basis

* On the MAT basis, the industry reported 7.9% growth YoY.

* Chronic therapies witnessed 9% YoY growth, while acute therapies displayed 6% YoY growth in Apr’25.

* Cardiac/Gastro/Antineoplast/Urology grew 11.3%/9.4%/12.6%/13.1% YoY. Respiratory/ Gynae/Ophthal underperformed IPM by 380bp/410bp/ 310bp on YoY basis.

* The acute segment’s share in overall IPM stood at 61% for MAT Apr’25, with YoY growth of 7.9%.

 

Domestic companies outperform MNCs in Apr’25

* As of Apr’25, Indian pharma companies hold a majority share of 83% in IPM, while the remaining is held by multi-national pharma companies (MNCs).

* In Mar’25, Indian companies grew 7.4%, while MNCs grew 7.4% YoY.

 

 

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here